Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Breast Neoplasms × milademetan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 1 Recurrence 1 Liposarcoma 1 Leukemia, Myeloid, Acute 1 Breast Neoplasms 1

Interventions

Trastuzumab 69 Capecitabine 54 Cyclophosphamide 50 Paclitaxel 48 Docetaxel 45 Fulvestrant 40 Letrozole 39 Lapatinib 30 Carboplatin 30 Doxorubicin 29 Vinorelbine 28 Bevacizumab 26 Anastrozole 23 pembrolizumab 22 exemestane 21 Tamoxifen 20 Gemcitabine 19 Albumin-Bound Paclitaxel 19 Radiotherapy 17 Taxes 15 Everolimus 14 Epirubicin 13 130-nm albumin-bound paclitaxel 13 palbociclib 12 pertuzumab 11 Magnetic Resonance Spectroscopy 11 Filgrastim 11 Ado-Trastuzumab Emtansine 11 liposomal doxorubicin 10 eribulin 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05932667 2023-12-21

DEMETER

Institut Curie

Phase 2 Terminated

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡